We can’t show the full text here under this license. Use the link below to read it at the source.
Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy
MGMT gene activity levels linked to outcomes in brain cancer treated with temozolomide and radiation
AI simplified
Abstract
Median overall survival for glioblastoma patients treated with temozolomide and radiotherapy was 12.4 months.
- Methylation of the MGMT promoter was found to be an independent prognostic factor associated with prolonged progression-free survival and overall survival.
- Cases with more than 35% methylation exhibited the longest survival, with a median progression-free survival of 19.2 months and overall survival of 26.2 months.
- Significant differences in progression-free survival were observed between patients with intermediate or high methylation compared to unmethylated cases.
- 86% of glioblastomas demonstrated homogeneous methylation status across multiple samples, indicating consistency in methylation patterns.
- 58 out of 109 glioblastomas showed average methylation levels greater than non-neoplastic brain tissue in at least one clinical sample.
AI simplified